<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>PULMICORT RESPULES - budesonide suspension </strong><br>Physicians Total Care, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">
<span class="Italics">These highlights do not include all the information needed to use PULMICORT RESPULES<span class="Sup">®</span> safely and effectively. See full prescribing information for PULMICORT RESPULES<span class="Sup">®</span> .</span><br>PULMICORT RESPULES<span class="Sup">®</span> (BUDESONIDE INHALATION SUSPENSION)<br>INITIAL U.S. APPROVAL 2000</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta"><span class="Italics">PULMICORT RESPULES®  is an inhaled corticosteroid  indicated for: </span>  (<a href="#section-1">1</a>)</p>
<p class="Highlighta">• 	Maintenance treatment of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> and as <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> therapy in children 12 months to 8 years of age (1.1)   (<a href="#section-1">1</a>)</p>
<p class="Highlighta"><span class="Underline">Important Limitations of Use: </span>  (<a href="#section-1">1</a>)</p>
<p class="Highlighta">Not indicated for the relief of acute <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> (1.1)  (<a href="#section-1">1</a>)</p>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta">Recommended dosing based on previous therapy (2). Start with the lowest recommended dose:  (<a href="#section-2">2</a>)</p>
<ul>
<li>Bronchodilators alone: 0.5 mg once daily or 0.25 mg twice daily</li>
<li><p class="Highlighta">Inhaled corticosteroids: 0.5 mg once daily or 0.25 mg twice daily up to 0.5 mg twice daily  (<a href="#section-2">2</a>)</p></li>
<li><p class="Highlighta">Oral corticosteroids: 0.5 mg twice daily or 1 mg once daily  (<a href="#section-2">2</a>)</p></li>
<li><p class="Highlighta">In symptomatic children not responding to non-steroidal therapy, a starting dose of 0.25 mg once daily may be considered.  (<a href="#section-2">2</a>)</p></li>
<li><p class="Highlighta">If once-daily treatment does not provide adequate control, the total daily dose should be increased and/or administered as a divided dose. Once <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> stability is achieved, titrate the dose downwards.  (<a href="#section-2">2</a>)</p></li>
<li><p class="Highlighta">For inhalation use via compressed air driven jet nebulizers only (not for use with ultrasonic devices). Not for injection. (2.2)  (<a href="#section-2">2</a>)</p></li>
</ul>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Inhalation suspension: 0.25 mg/2mL, 0.5 mg/2mL, 1 mg/2mL (3)  (<a href="#section-3">3</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div>
<p class="Highlighta">• 	Primary treatment of status asthmaticus or other acute episodes of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> where intensive measures are required. (4.1)  (<a href="#section-4">4</a>)</p>
<p class="Highlighta">• 	<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to any of the ingredients in PULMICORT RESPULES (4.2)  (<a href="#section-4">4</a>)</p>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li><p class="Highlighta"><span class="product-label-link" type="condition" conceptid="4018050" conceptname="Localized infection">Localized infections</span>: <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> albicans</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> of the mouth and throat may occur. Monitor patients periodically for signs of adverse effects on the oral cavity. Advise patients to rinse the mouth following inhalation. (5.1)  (<a href="#section-5">5</a>)</p></li>
<li><p class="Highlighta">Deterioration of disease and acute <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> episodes: Do not use for the relief of acute <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>. (5.2)  (<a href="#section-5">5</a>)</p></li>
<li><p class="Highlighta"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span>: <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">contact dermatitis</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, and <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> have been reported with use of PULMICORT RESPULES. Discontinue PULMICORT RESPULES if such reactions occur (5.3)  (<a href="#section-5">5</a>)</p></li>
<li><p class="Highlighta"><span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">Immunosuppression</span>: Potential worsening of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (e.g., existing <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>, fungal, bacterial, viral, or parasitic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>; or ocular herpes simplex). Use with caution in patients with these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. More serious or even fatal course of <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span> or <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span> can occur in susceptible patients. (5.4)  (<a href="#section-5">5</a>)</p></li>
<li><p class="Highlighta">Transferring patients from systemic corticosteroids: Risk of impaired adrenal function when transferring from oral steroids. Taper patients slowly from systemic corticosteroids if transferring to PULMICORT RESPULES. (5.5)  (<a href="#section-5">5</a>)</p></li>
<li><p class="Highlighta">Hypercorticism and adrenal suppression: May occur with very high dosages or at the regular dosage in susceptible individuals. If such changes occur, reduce PULMICORT RESPULES slowly. (5.6)  (<a href="#section-5">5</a>)</p></li>
<li><p class="Highlighta">Reduction in bone mineral density with long term administration.  Monitor patients with major risk factors for decreased bone mineral content. (5.7)  (<a href="#section-5">5</a>)</p></li>
<li><p class="Highlighta">Effects on growth: Monitor growth of pediatric patients. (5.8)  (<a href="#section-5">5</a>)</p></li>
<li><p class="Highlighta"><span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span> and <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataracts</span>: Close monitoring is warranted. (5.9)  (<a href="#section-5">5</a>)</p></li>
<li><p class="Highlighta"><span class="product-label-link" type="condition" conceptid="4010475" conceptname="Paradoxical bronchospasm">Paradoxical bronchospasm</span>: Discontinue PULMICORT RESPULES and institute alternative therapy if <span class="product-label-link" type="condition" conceptid="4010475" conceptname="Paradoxical bronchospasm">paradoxical bronchospasm</span> occurs. (5.10)  (<a href="#section-5">5</a>)</p></li>
<li><p class="Highlighta">Eosinophilic conditions and Churg-Strauss syndrome: Be alert to eosinophilic conditions. (5.11)    (<a href="#section-5">5</a>)</p></li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Adverse reactions at an incidence of <span class="Underline">&gt;</span>3%:   (<a href="#section-6">6</a>)</p>
<p class="Highlighta"><span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">Respiratory infection</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span>, <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span>, <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infection</span>, <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">moniliasis</span>, <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4044878" conceptname="Infection of ear">ear infection</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (6.1)  (<a href="#section-6">6</a>)</p>
<p class="Highlighta">  (<a href="#section-6">6</a>)</p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact AstraZeneca at 1–800–236–9933 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch</span>  (<a href="#section-6">6</a>)</p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul><li><p class="Highlighta">Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Use with caution. May cause increased systemic corticosteroid effects. (5.12, 7.1)  (<a href="#section-7">7</a>)</p></li></ul></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION, and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 6/2012</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Maintenance Treatment of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Dosing Recommendations</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Directions for Use</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS </a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Local Effects</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Deterioration of Disease and Acute <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span> Episodes</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span> Including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">Immunosuppression</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Transferring Patients from Systemic Corticosteroid Therapy</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Hypercorticism and Adrenal Suppression</a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Reduction in Bone Mineral Density</a></h2>
<h2><a href="#section-5.8" class="toc">5.8 Effects on Growth</a></h2>
<h2><a href="#section-5.9" class="toc">5.9 <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span> and <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">Cataracts</span></a></h2>
<h2><a href="#section-5.10" class="toc">5.10 <span class="product-label-link" type="condition" conceptid="4010475" conceptname="Paradoxical bronchospasm">Paradoxical Bronchospasm</span> and Upper Airway Symptoms</a></h2>
<h2><a href="#section-5.11" class="toc">5.11 Eosinophilic Conditions and Churg-Strauss Syndrome</a></h2>
<h2><a href="#section-5.12" class="toc">5.12 Drug Interactions with Strong Cytochrome P450 3A4 Inhibitors</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Post-marketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Inhibitors of Cytochrome P450 3A4</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2 Animal Toxicology Reproductive Toxicology</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING </a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc"></a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.1"></a><p></p>
<h2>1.1 Maintenance Treatment of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></h2>
<p class="First">PULMICORT RESPULES is indicated for the maintenance treatment of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> and as <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> therapy in children 12 months to 8 years of age.  </p>
<p>Important Limitations of Use: </p>
<p>• 	PULMICORT RESPULES is NOT indicated for the relief of acute <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="nelsonjk1279119223667"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First"> The recommended starting dose and highest recommended dose of PULMICORT RESPULES, based on prior <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> therapy, are listed in the following table.</p>
<a name="iefe4bc3e-0487-4701-8c62-9e3f63339a7d"></a><table frame="hsides">
<colgroup>
<col align="left" valign="top">
<col align="left" valign="top">
<col align="left" valign="top">
</colgroup>
<thead><tr class="Botrule First Last">
<th align="left">Previous Therapy</th>
<th align="left">Recommended Starting Dose</th>
<th align="left">Highest Recommended Dose</th>
</tr></thead>
<tbody>
<tr class="First">
<td align="left"><p class="First"><span class="Bold">Bronchodilators alone</span></p></td>
<td align="left"><p class="First">0.5 mg total daily dose administered either once daily or twice daily in divided doses</p></td>
<td align="left"><p class="First">0.5 mg total daily dose</p></td>
</tr>
<tr>
<td align="left"><p class="First"><span class="Bold">Inhaled Corticosteroids</span></p></td>
<td align="left"><p class="First">0.5 mg total daily dose administered either once daily or twice daily in divided doses</p></td>
<td align="left"><p class="First">1 mg total daily dose</p></td>
</tr>
<tr class="Last">
<td align="left"><p class="First"><span class="Bold">Oral Corticosteroids</span></p></td>
<td align="left"><p class="First">1 mg total daily dose administered either as 0.5 mg twice daily or 1 mg once daily</p></td>
<td align="left"><p class="First">1 mg total daily dose</p></td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1"></a><p></p>
<h2>2.1 Dosing Recommendations</h2>
<p class="First">Dosing recommendations based on previous therapy are as follows:</p>
<ul>
<li><p class="First">Bronchodilators alone: 0.5 mg once daily or 0.25 mg twice daily</p></li>
<li><p class="First">Inhaled corticosteroids: 0.5 mg once daily or 0.25 mg twice daily up to 0.5 mg twice daily</p></li>
<li><p class="First">Oral corticosteroids: 0.5 mg twice daily or 1 mg once daily</p></li>
</ul>
<p>In symptomatic children not responding to non-steroidal therapy, a starting dose of 0.25 mg once daily may be considered. If once-daily treatment does not provide adequate control, the total daily dose should be increased and/or administered as a divided dose. In all patients, it is desirable to downward-titrate to the lowest effective dose once <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> stability is achieved.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2"></a><p></p>
<h2>2.2 Directions for Use</h2>
<p class="First">PULMICORT RESPULES should be administered via jet nebulizer connected to an air compressor with an adequate air flow, equipped with a mouthpiece or suitable face mask.  Ultrasonic nebulizers are not suitable for the adequate administration of PULMICORT RESPULES and, therefore, are NOT recommended.  </p>
<p>The effects of mixing PULMICORT RESPULES with other nebulizable medications have not been adequately assessed.  PULMICORT RESPULES should be administered separately in the nebulizer [see <span class="Italics"><a href="#nelsonjk1279120227289">Patient Counseling Information, Administration with a jet nebulizer (17.1)</a></span>].  </p>
<p>A Pari-LC-Jet Plus Nebulizer (with face mask or mouthpiece) connected to a Pari Master compressor was used to deliver PULMICORT RESPULES to each patient in 3 U.S. controlled clinical studies.  The safety and efficacy of PULMICORT RESPULES delivered by other nebulizers and compressors have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS </h1>
<p class="First">PULMICORT RESPULES is available in three strengths, each containing 2 mL: 0.25 mg/2 mL, 0.5 mg/2mL, and 1 mg/2 mL.  PULMICORT RESPULES is supplied in sealed aluminum foil envelopes containing one plastic strip of five single-dose RESPULES ampules together with patient instructions for use.  There are 30 RESPULES ampules in a carton.  Each single-dose RESPULES ampule contains 2 mL of sterile liquid suspension.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="nelsonjk1279067428237"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">The use of PULMICORT RESPULES is contraindicated in the following conditions:</p>
<p>·	Primary treatment of status asthmaticus or other acute episodes of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> where intensive measures are required.</p>
<p>·	<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to budesonide or any of the ingredients of PULMICORT RESPULES [see <span class="Italics"><a href="#nelsonjk1279119388961">Warnings and Precautions (5.3),</a><a href="#nelsonjk1279120277850">Description (11) </a>and <a href="#nelsonjk1279120296928">Adverse Reactions, Post-marketing Experience (6.2)</a></span>].</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.1"></a><p></p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="nelsonjk1279119355555"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Local Effects</h2>
<p class="First">In clinical trials with PULMICORT RESPULES, <span class="product-label-link" type="condition" conceptid="4018050" conceptname="Localized infection">localized infections</span> with <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> albicans</span> occurred in the mouth and pharynx in some patients. The incidences of <span class="product-label-link" type="condition" conceptid="4018050" conceptname="Localized infection">localized infections</span> of <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> albicans</span> were similar between the placebo and PULMICORT RESPULES treatment groups.  If these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> develop, they may require treatment with appropriate local or systemic antifungal therapy and/or discontinuance of treatment with PULMICORT RESPULES. Patients should rinse the mouth after inhalation of PULMICORT RESPULES.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="nelsonjk1279120044261"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Deterioration of Disease and Acute <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span> Episodes</h2>
<p class="First">PULMICORT RESPULES is not a bronchodilator and is not indicated for the rapid relief of acute <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> or other acute episodes of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>.</p>
<p>Patients should be instructed to contact their physician immediately if episodes of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> not responsive to their usual doses of bronchodilators occur during the course of  treatment with PULMICORT RESPULES. During such episodes, patients may require therapy with oral corticosteroids.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="nelsonjk1279119388961"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span> Including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">contact dermatitis</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, and <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> have been reported with use of PULMICORT RESPULES.  Discontinue PULMICORT RESPULES if such reactions occur [<span class="Italics">see <a href="#nelsonjk1279067428237">Contraindications (4)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="nelsonjk1279119412992"></a><a name="section-5.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">Immunosuppression</span></h2>
<p class="First">Patients who are on drugs that suppress the immune system are more susceptible to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> than healthy individuals.  Chicken pox and <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>, for example, can have a more serious or even fatal course in susceptible children or adults using corticosteroids.  In children or adults who have not had these diseases, or been properly immunized, particular care should be taken to avoid exposure. How the dose, route, and duration of corticosteroid administration affect the risk of developing a disseminated <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> is not known.  The contribution of the underlying disease and/or prior corticosteroid treatment to the risk is also not known.  If exposed to chicken pox, therapy with <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">varicella zoster</span> immune globulin (VZIG) or pooled intravenous immunoglobulin (IVIG), as appropriate, may be indicated. If exposed to <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>, prophylaxis with pooled intramuscular immunoglobulin (IG) may be indicated. (See the respective package inserts for complete VZIG and IG prescribing information.)  If chicken pox develops, treatment with antiviral agents may be considered.   </p>
<p>The clinical course of chicken pox or <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> in patients on inhaled corticosteroids has not been studied.  However, a clinical study has examined the immune responsiveness of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> patients 12 months to 8 years of age who were treated with PULMICORT RESPULES. An open-label non-randomized clinical study examined the immune responsiveness of <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span> vaccine in 243 <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> patients 12 months to 8 years of age who were treated with PULMICORT RESPULES 0.25 mg to 1 mg daily (n=151) or noncorticosteroid <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> therapy (n=92) (i.e., beta<span class="Sub">2</span>-agonists, leukotriene receptor antagonists, cromones). The percentage of patients developing a seroprotective antibody titer of ≥5.0 (gpELISA value) in response to the vaccination was similar in patients treated with PULMICORT RESPULES (85%) compared to patients treated with non-corticosteroid <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> therapy (90%). No patient treated with PULMICORT RESPULES developed chicken pox as a result of vaccination. </p>
<p>Inhaled corticosteroids should be used with caution, if at all, in patients with active or quiescent <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> of the respiratory tract, untreated systemic fungal, bacterial, viral, or parasitic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>; or ocular herpes simplex.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="nelsonjk1279119568739"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Transferring Patients from Systemic Corticosteroid Therapy</h2>
<p class="First">Particular care is needed for patients who are transferred from systemically active corticosteroids to inhaled corticosteroids because <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> due to <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span> have occurred in <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> patients during and after transfer from systemic corticosteroids to less systemically available inhaled corticosteroids. After withdrawal from systemic corticosteroids, a number of months are required for recovery of hypothalamic-pituitary-adrenal (HPA)-axis function.  </p>
<p>Patients who have been previously maintained on 20 mg or more per day of prednisone (or its equivalent) may be most susceptible, particularly when their systemic corticosteroids have been almost completely withdrawn.  </p>
<p>During this period of HPA-axis suppression, patients may exhibit signs and symptoms of <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span> when exposed to <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, surgery, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (particularly <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>) or other conditions associated with severe electrolyte loss.  Although PULMICORT RESPULES may provide control of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> symptoms during these episodes, in recommended doses it supplies less than normal physiological amounts of glucocorticosteroid systemically and does NOT provide the mineralocorticoid activity that is necessary for coping with these emergencies.</p>
<p>During periods of stress or a severe <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attack, patients who have been withdrawn from systemic corticosteroids should be instructed to resume oral corticosteroids (in large doses) immediately and to contact their physicians for further instructions.  These patients should also be instructed to carry a medical identification card indicating that they may need supplementary systemic corticosteroids during periods of stress or a severe <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attack.</p>
<p>Patients requiring oral corticosteroids should be weaned slowly from systemic corticosteroid use after transferring to PULMICORT RESPULES. Initially, PULMICORT RESPULES should be used concurrently with the patient’s usual maintenance dose of systemic corticosteroid.  After approximately one week, gradual withdrawal of the systemic corticosteroid may be initiated by reducing the daily or alternate daily dose. Further incremental reductions may be made after an interval of one or two weeks, depending on the response of the patient. Generally, these decrements should not exceed 25% of the prednisone dose or its equivalent.  A slow rate of withdrawal is strongly recommended.</p>
<p>Lung function (FEV<span class="Sub">1</span> or AM PEF), beta-agonist use, and <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> symptoms should be carefully monitored during withdrawal of oral corticosteroids. In addition to monitoring <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> signs and symptoms, patients should be observed for signs and symptoms of <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span> such as <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">lassitude</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>.  </p>
<p>Transfer of patients from systemic corticosteroid therapy to PULMICORT RESPULES may unmask allergic or other immunologic conditions previously suppressed by the systemic corticosteroid therapy, e.g., <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, eosinophilic conditions, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">eczema</span>, and <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span> [see <span class="Italics"><a href="#nelsonjk1279119223667">Dosage and Administration (2)</a></span>].</p>
<p>During withdrawal from oral corticosteroids, patients may experience symptoms of systemically active corticosteroid withdrawal (e.g., joint and/or <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscular pain</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">lassitude</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>) despite maintenance or even improvement of respiratory function.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="nelsonjk1279119432632"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Hypercorticism and Adrenal Suppression</h2>
<p class="First">PULMICORT RESPULES, will often help control <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> symptoms with less suppression of HPA function than therapeutically equivalent oral doses of prednisone. Since individual sensitivity to effects on cortisol production exists, physicians should consider this information when prescribing PULMICORT RESPULES. Because of the possibility of systemic absorption of inhaled corticosteroids, patients treated with PULMICORT RESPULES should be observed carefully for any evidence of systemic corticosteroid effects.  Particular care should be taken in observing patients post-operatively or during periods of stress for evidence of inadequate adrenal response. It is possible that systemic corticosteroid effects such as hypercorticism, and adrenal suppression (including <span class="product-label-link" type="condition" conceptid="4088744" conceptname="Severe adrenal insufficiency">adrenal crisis</span>) may appear in a small number of patients, particularly when budesonide is administered at higher than recommended doses over <span class="product-label-link" type="condition" conceptid="4088438" conceptname="Prolonged periods">prolonged periods</span> of time.  If such effects occur, the dosage of PULMICORT RESPULES should be reduced slowly, consistent with accepted procedures for tapering of systemic corticosteroids and for management of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="nelsonjk1279119451835"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Reduction in Bone Mineral Density</h2>
<p class="First">Decreases in bone mineral density (BMD) have been observed with long-term administration of products containing inhaled corticosteroids. The clinical significance of small changes in BMD with regard to long-term outcomes is unknown.  Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>, poor nutrition, or chronic use of drugs that can reduce bone <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> (e.g., anticonvulsants and corticosteroids), should be monitored and treated with established standards of care.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="nelsonjk1279067620485"></a><a name="section-5.8"></a><p></p>
<h2>5.8 Effects on Growth</h2>
<p class="First">Orally inhaled corticosteroids, including budesonide, may cause a reduction in growth velocity when administered to pediatric patients. Monitor the growth of pediatric patients receiving PULMICORT RESPULES routinely (e.g., via stadiometry). To minimize the systemic effects of orally inhaled corticosteroids, including PULMICORT RESPULES, each patient should be titrated to his/her lowest effective dose [see <span class="Italics"><a href="#nelsonjk1279067656532">Use In Specific Populations, Pediatric Use (8.4)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="nelsonjk1279066943771"></a><a name="section-5.9"></a><p></p>
<h2>5.9 <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span> and <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">Cataracts</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span>, <span class="product-label-link" type="condition" conceptid="4011560" conceptname="Raised intraocular pressure">increased intraocular pressure</span>, and <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataracts</span> have been reported following the long-term administration of inhaled corticosteroids, including budesonide.  Therefore, close monitoring is warranted in patients with a change in vision or with a history of <span class="product-label-link" type="condition" conceptid="4011560" conceptname="Raised intraocular pressure">increased intraocular pressure</span>, <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, and/or <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataracts</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="nelsonjk1279067463283"></a><a name="section-5.10"></a><p></p>
<h2>5.10 <span class="product-label-link" type="condition" conceptid="4010475" conceptname="Paradoxical bronchospasm">Paradoxical Bronchospasm</span> and Upper Airway Symptoms</h2>
<p class="First">As with other inhaled <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> medications, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, with an immediate increase in <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, may occur after dosing.  If acute <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> occurs following dosing with PULMICORT RESPULES, it should be treated immediately with a fast-acting inhaled bronchodilator. Treatment with PULMICORT RESPULES should be discontinued and alternate therapy instituted.  </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="nelsonjk1279119544536"></a><a name="section-5.11"></a><p></p>
<h2>5.11 Eosinophilic Conditions and Churg-Strauss Syndrome</h2>
<p class="First">In rare cases, patients on inhaled corticosteroids may present with systemic eosinophilic conditions. Some of these patients have clinical features of <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span> consistent with Churg- Strauss syndrome, a condition that is often treated with systemic corticosteroids therapy. These events usually, but not always, have been associated with the reduction and/or withdrawal of oral corticosteroid therapy following the introduction of inhaled corticosteroids. Healthcare providers should be alert to <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span> <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, worsening pulmonary symptoms, cardiac complications, and/or <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span> presenting in their patients. A causal relationship between budesonide and these underlying conditions has not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="nelsonjk1279119598129"></a><a name="section-5.12"></a><p></p>
<h2>5.12 Drug Interactions with Strong Cytochrome P450 3A4 Inhibitors</h2>
<p class="First">Caution should be exercised when considering the coadministration of PULMICORT RESPULES with ketoconazole, and other known strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) because adverse effects related to increased systemic exposure to budesonide may occur [see <span class="Italics"><a href="#nelsonjk1279119306431">Drug Interactions (7.1)</a>and <a href="#nelsonjk1279119335993">Clinical Pharmacology, Clinical Pharmacokinetics (12.3)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">Systemic and inhaled corticosteroid use may result in the following:</p>
<ul>
<li><p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> albicans</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> [see <span class="Italics"><a href="#nelsonjk1279119355555">Warnings and Precautions (5.1)</a></span>]</p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> [see <span class="Italics"><a href="#nelsonjk1279119388961">Warnings and Precautions (5.3)</a></span>]</p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">Immunosuppression</span> [see <span class="Italics"><a href="#nelsonjk1279119412992">Warnings and Precautions (5.4)</a></span>]</p></li>
<li><p class="First">Hypercorticism and adrenal suppression [see <span class="Italics"><a href="#nelsonjk1279119432632">Warnings and Precautions (5.6)</a></span>]</p></li>
<li><p class="First">Reduction in bone mineral density [see <span class="Italics"><a href="#nelsonjk1279119451835">Warnings and Precautions (5.7)</a></span>]</p></li>
<li><p class="First">Growth effects in pediatric patients [see <span class="Italics"><a href="#nelsonjk1279067620485">Warnings and Precautions (5.8)</a>and <a href="#nelsonjk1279067656532">Use in Specific Populations, Pediatric Use (8.4)</a></span>]</p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span>, <span class="product-label-link" type="condition" conceptid="4011560" conceptname="Raised intraocular pressure">increased intraocular pressure</span> and <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataracts</span> [see <span class="Italics"><a href="#nelsonjk1279066943771">Warnings and Precautions (5.9)</a></span>]</p></li>
<li><p class="First">Eosinophilic conditions and Churg-Strauss syndrome [see <span class="Italics"><a href="#nelsonjk1279119544536">Warnings and Precautions (5.11)</a></span>]</p></li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="nelsonjk1279119707252"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>The incidence of common adverse reactions is based on three double-blind, placebo-controlled, randomized U.S. clinical trials in which 945 patients, 12 months to 8 years of age, (98 patients ≥12 months and &lt;2 years of age; 225 patients ≥2 and &lt;4 years of age; and 622 patients ≥4 and ≤8 years of age) were treated with PULMICORT RESPULES (0.25 to 1 mg total daily dose for 12 weeks) or vehicle placebo.  The incidence and nature of adverse events reported for PULMICORT RESPULES was comparable to that reported for placebo.  The following table shows the incidence of adverse events in U.S. controlled clinical trials, regardless of relationship to treatment, in patients previously receiving bronchodilators and/or inhaled corticosteroids. This population included a total of 605 male and 340 female patients and 78.4% were Caucasian, 13.8% African American, 5.5% Hispanic and 2.3% Other.</p>
<a name="i0a40d12c-bc44-490f-8dda-e32d1cdf64b6"></a><table frame="hsides">
<caption><span>Table 1 – Adverse Reactions occurring at an incidence of ≥3% in at least one active treatment group where the incidence was higher with PULMICORT RESPULES than placebo</span></caption>
<colgroup>
<col align="left" valign="top">
<col align="left" valign="top">
<col align="left" valign="top">
<col align="left" valign="top">
<col align="left" valign="top">
</colgroup>
<tbody class="Headless">
<tr class="First">
<td align="left" rowspan="2"><p class="First">Adverse Events</p></td>
<td align="left" rowspan="2">
<p class="First">Vehicle Placebo</p>
<p>(n=227)</p>
<p>%</p>
</td>
<td align="left" colspan="3">
<p class="First">PULMICORT RESPULES</p>
<p>Total Daily Dose</p>
</td>
</tr>
<tr>
<td align="left">
<p class="First">0.25 mg</p>
<p>(n=178)</p>
<p>%</p>
</td>
<td align="left">
<p class="First">0.5 mg</p>
<p>(n=223)</p>
<p>%</p>
</td>
<td align="left">
<p class="First">1 mg</p>
<p>(n=317)</p>
<p>%</p>
</td>
</tr>
<tr><td align="left" colspan="5"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">Respiratory System Disorder</span></span></p></td></tr>
<tr>
<td align="left"><p class="First"><span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">Respiratory Infection</span></p></td>
<td align="left"><p class="First">36</p></td>
<td align="left"><p class="First">34</p></td>
<td align="left"><p class="First">35</p></td>
<td align="left"><p class="First">38</p></td>
</tr>
<tr>
<td align="left"><p class="First"><span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">Rhinitis</span></p></td>
<td align="left"><p class="First">9</p></td>
<td align="left"><p class="First">7</p></td>
<td align="left"><p class="First">11</p></td>
<td align="left"><p class="First">12</p></td>
</tr>
<tr>
<td align="left"><p class="First"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Coughing</span></p></td>
<td align="left"><p class="First">5</p></td>
<td align="left"><p class="First">5</p></td>
<td align="left"><p class="First">9</p></td>
<td align="left"><p class="First">8</p></td>
</tr>
<tr><td align="left" colspan="5"><p class="First"><span class="Bold">Resistance Mechanism Disorders</span></p></td></tr>
<tr>
<td align="left"><p class="First"><span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">Otitis Media</span></p></td>
<td align="left"><p class="First">11</p></td>
<td align="left"><p class="First">12</p></td>
<td align="left"><p class="First">11</p></td>
<td align="left"><p class="First">9</p></td>
</tr>
<tr>
<td align="left"><p class="First"><span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">Viral Infection</span></p></td>
<td align="left"><p class="First">3</p></td>
<td align="left"><p class="First">4</p></td>
<td align="left"><p class="First">5</p></td>
<td align="left"><p class="First">3</p></td>
</tr>
<tr>
<td align="left"><p class="First"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Moniliasis</span></p></td>
<td align="left"><p class="First">2</p></td>
<td align="left"><p class="First">4</p></td>
<td align="left"><p class="First">3</p></td>
<td align="left"><p class="First">4</p></td>
</tr>
<tr><td align="left" colspan="5"><p class="First"><span class="Bold">Gastrointestinal System Disorders</span></p></td></tr>
<tr>
<td align="left"><p class="First"><span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">Gastroenteritis</span></p></td>
<td align="left"><p class="First">4</p></td>
<td align="left"><p class="First">5</p></td>
<td align="left"><p class="First">5</p></td>
<td align="left"><p class="First">5</p></td>
</tr>
<tr>
<td align="left"><p class="First"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td align="left"><p class="First">3</p></td>
<td align="left"><p class="First">2</p></td>
<td align="left"><p class="First">4</p></td>
<td align="left"><p class="First">4</p></td>
</tr>
<tr>
<td align="left"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td align="left"><p class="First">2</p></td>
<td align="left"><p class="First">4</p></td>
<td align="left"><p class="First">4</p></td>
<td align="left"><p class="First">2</p></td>
</tr>
<tr>
<td align="left"><p class="First"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span></p></td>
<td align="left"><p class="First">2</p></td>
<td align="left"><p class="First">3</p></td>
<td align="left"><p class="First">2</p></td>
<td align="left"><p class="First">3</p></td>
</tr>
<tr><td align="left" colspan="5"><p class="First"><span class="Bold">Hearing and <span class="product-label-link" type="condition" conceptid="81303" conceptname="Labyrinthine disorder">Vestibular Disorders</span></span></p></td></tr>
<tr>
<td align="left"><p class="First"><span class="product-label-link" type="condition" conceptid="4044878" conceptname="Infection of ear">Ear Infection</span></p></td>
<td align="left"><p class="First">4</p></td>
<td align="left"><p class="First">2</p></td>
<td align="left"><p class="First">4</p></td>
<td align="left"><p class="First">5</p></td>
</tr>
<tr><td align="left" colspan="5"><p class="First"><span class="Bold">Platelet, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> and <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">Clotting Disorders</span></span></p></td></tr>
<tr>
<td align="left"><p class="First"><span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Epistaxis</span></p></td>
<td align="left"><p class="First">1</p></td>
<td align="left"><p class="First">2</p></td>
<td align="left"><p class="First">4</p></td>
<td align="left"><p class="First">3</p></td>
</tr>
<tr><td align="left" colspan="5"><p class="First"><span class="Bold">Vision Disorders</span></p></td></tr>
<tr>
<td align="left"><p class="First"><span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">Conjunctivitis</span></p></td>
<td align="left"><p class="First">2</p></td>
<td align="left"><p class="First">&lt;1</p></td>
<td align="left"><p class="First">4</p></td>
<td align="left"><p class="First">2</p></td>
</tr>
<tr><td align="left" colspan="5"><p class="First"><span class="Bold">Skin and Appendages Disorders</span></p></td></tr>
<tr class="Last">
<td align="left"><p class="First"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></p></td>
<td align="left"><p class="First">3</p></td>
<td align="left"><p class="First">&lt;1</p></td>
<td align="left"><p class="First">4</p></td>
<td align="left"><p class="First">2</p></td>
</tr>
</tbody>
</table>
<p>The information below includes all adverse reactions  by system organ class with an incidence of 1 to &lt; 3%, in at least one PULMICORT RESPULES treatment group where the incidence was higher with PULMICORT RESPULES than with placebo, regardless of relationship to treatment.</p>
<p><span class="Italics">Blood and lymphatic system disorders:</span> cervical <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span> </p>
<p><span class="Italics">Ear and labyrinth disorders: </span> <span class="product-label-link" type="condition" conceptid="380733" conceptname="Otalgia">earache</span> </p>
<p><span class="Italics">General disorders and administration site conditions:</span>  <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, flu-like disorder </p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune system disorders</span>:</span>  <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> </p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestations</span>:</span>  <span class="product-label-link" type="condition" conceptid="4134613" conceptname="Eye infection">eye infection</span>, herpes simplex, external <span class="product-label-link" type="condition" conceptid="4044878" conceptname="Infection of ear">ear infection</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> </p>
<p><span class="Italics">Injury, <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> and procedural complication:</span>  <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> </p>
<p><span class="Italics">Metabolism and nutrition disorders:</span> <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span> </p>
<p><span class="Italics">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">connective tissue disorders</span>:</span>  <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span> </p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span>:</span>  <span class="product-label-link" type="condition" conceptid="4195305" conceptname="Hyperactive behavior">hyperkinesia</span> </p>
<p><span class="Italics">Psychiatric disorders:</span>  <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span> </p>
<p><span class="Italics">Respiratory, thoracic, and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorders</span>:</span>  <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="432730" conceptname="Difficulty speaking">dysphonia</span>, <span class="product-label-link" type="condition" conceptid="253321" conceptname="Stridor">stridor</span> </p>
<p><span class="Italics">Skin and subcutaneous tissue disorders:</span>  <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">contact dermatitis</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">eczema</span>, <span class="product-label-link" type="condition" conceptid="4158333" conceptname="Pustule">pustular rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>  </p>
<p>The incidence of reported adverse events was similar between the 447 PULMICORT RESPULES-treated (mean total daily dose 0.5 to 1 mg) and 223 conventional therapy-treated pediatric <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> patients followed for one year in three open-label studies.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="nelsonjk1279120296928"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Post-marketing Experience</h2>
<p class="First">The following adverse reactions have been reported during post-approval use of PULMICORT RESPULES.  Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.  Some of these adverse reactions may also have been observed in clinical studies with PULMICORT RESPULES.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="31821" conceptname="Disorder of endocrine system">Endocrine disorders</span>:</span> symptoms of hypocorticism and hypercorticism [see <span class="Italics"><a href="#nelsonjk1279119568739">Warnings and Precautions (5.5)</a></span>]</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye disorders</span>:</span>  <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataracts</span>, <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, <span class="product-label-link" type="condition" conceptid="4011560" conceptname="Raised intraocular pressure">increased intraocular pressure</span> [see <a href="#nelsonjk1279066943771">Warnings and Precautions (5.9)</a>]</p>
<p><span class="Italics">General disorders and administration site conditions:</span>  <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune system disorders</span>:</span> immediate and delayed <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> including, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">contact dermatitis</span>, and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> [see <a href="#nelsonjk1279067428237">Contraindications (4)</a>and <a href="#nelsonjk1279067463283">Warnings and Precautions (5.10)</a>]</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestation</span>:</span>  <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span></p>
<p><span class="Italics">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">connective tissue disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="77650" conceptname="Aseptic necrosis of bone">avascular necrosis</span> of the femoral head, <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>, <span class="product-label-link" type="condition" conceptid="4245750" conceptname="Growth retardation">growth suppression</span> </p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span>:</span>  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></p>
<p><span class="Italics">Psychiatric disorders:</span>  <span class="product-label-link" type="condition" conceptid="4294810" conceptname="Psychiatric symptom">psychiatric symptoms</span> including <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressive reactions</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, and <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> </p>
<p><span class="Italics">Respiratory, thoracic, and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorders</span>:</span>  <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="432730" conceptname="Difficulty speaking">dysphonia</span> and <span class="product-label-link" type="condition" conceptid="4038048" conceptname="Throat irritation">throat irritation</span> </p>
<p><span class="Italics">Skin and subcutaneous tissue disorders:</span>  skin <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span>, facial <span class="product-label-link" type="condition" conceptid="4280604" conceptname="Skin irritation">skin irritation</span></p>
<p>Cases of <span class="product-label-link" type="condition" conceptid="4245750" conceptname="Growth retardation">growth suppression</span> have been reported for inhaled corticosteroids including post-marketing reports for PULMICORT RESPULES [see <span class="Italics"><a href="#nelsonjk1279067620485">Warnings and Precautions (5.8)</a>and <a href="#nelsonjk1279067656532">Use In Specific Populations, Pediatric Use (8.4)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="nelsonjk1279119306431"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Inhibitors of Cytochrome P450 3A4</h2>
<p class="First">The main route of metabolism of corticosteroids, including budesonide, is via cytochrome P450 (CYP) isoenzyme 3A4 (CYP3A4). After oral administration of ketoconazole, a strong inhibitor of CYP3A4, the mean plasma concentration of orally administered budesonide increased. Concomitant administration of a CYP3A4 inhibitor may inhibit the metabolism of, and increase the systemic exposure to, budesonide. Caution should be exercised when considering the coadministration of PULMICORT RESPULES with long-term ketoconazole and other known strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) [see <span class="Italics"><a href="#nelsonjk1279119598129">Warnings and Precautions (5.12)</a>and <a href="#nelsonjk1279119335993">Clinical Pharmacology, Pharmacokinetics (12.3)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Italics">Teratogenic Effects: Pregnancy Category B</span> – Studies of pregnant women, have not shown that inhaled budesonide increases the risk of abnormalities when administered during pregnancy.  The results from a large population-based prospective cohort epidemiological study reviewing data from three Swedish registries covering approximately 99% of the pregnancies from 1995-1997 (ie, Swedish Medical Birth Registry; Registry of Congenital Malformations; Child Cardiology Registry) indicate no increased risk for congenital malformations from the use of inhaled budesonide during early pregnancy.  Congenital malformations were studied in 2014 infants born to mothers reporting the use of inhaled budesonide for <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> in early pregnancy (usually 10-12 weeks after the last menstrual period), the period when most major organ malformations occur.  The rate of recorded congenital malformations was similar compared to the general population rate (3.8% vs. 3.5%, respectively).  In addition, after exposure to inhaled budesonide, the number of infants born with orofacial clefts was similar to the expected number in the normal population (4 children vs. 3.3, respectively). </p>
<p>These same data were utilized in a second study bringing the total to 2534 infants whose mothers were exposed to inhaled budesonide.  In this study, the rate of congenital malformations among infants whose mothers were exposed to inhaled budesonide during early pregnancy was not different from the rate for all newborn babies during the same period (3.6%).  </p>
<p>Despite the animal findings, it would appear that the possibility of fetal harm is remote if the drug is used during pregnancy.  Nevertheless, because the studies in humans cannot rule out the possibility of harm, PULMICORT RESPULES should be used during pregnancy only if clearly needed.</p>
<p>As with other corticosteroids, budesonide was teratogenic and embryocidal in rabbits and rats.  Budesonide produced fetal loss, decreased pup weights, and skeletal abnormalities at a subcutaneous dose in rabbits that was approximately 0.4 times the maximum recommended daily inhalation dose in adults on a mcg/m<span class="Sup">2</span> basis and at subcutaneous dose that was approximately 4 times the maximum recommended daily inhalation dose in adults on a mcg/m<span class="Sup">2</span> basis.  In another study in rats, no teratogenic or embryocidal effects were seen at inhalation doses up to approximately 2 times the maximum recommended daily inhalation dose in adults on a mcg/m<span class="Sup">2</span> basis.  </p>
<p></p>
<p>Experience with oral corticosteroids since their introduction in pharmacologic, as opposed to physiologic, doses suggests that rodents are more prone to teratogenic effects from corticosteroids than humans.</p>
<p></p>
<p><span class="Italics">Non-teratogenic Effects:</span></p>
<p><span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">Hypoadrenalism</span> may occur in infants born of mothers receiving corticosteroids during pregnancy.  Such infants should be carefully observed.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="nelsonjk1279119665034"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Budesonide, like other corticosteroids, is secreted in human milk.  Data with budesonide delivered via dry powder inhaler indicates that the total daily oral dose of budesonide in breast milk to the infant is approximately 0.3% to 1% of the dose inhaled by the mother [see <span class="Italics"><a href="#nelsonjk1279119335993">Clinical Pharmacology, Pharmacokinetics (12.3),</a>and <a href="#nelsonjk1279119665034">Use In Specific Populations, Nursing Mothers (8.3)</a></span>].  No studies have been conducted in breastfeeding women with PULMICORT RESPULES; however, the dose of budesonide available to the infant in breast milk, as a percentage of the maternal dose, would be expected to be similar.  PULMICORT RESPULES should be used in nursing women only if clinically appropriate.  Prescribers should weigh the known benefits of breastfeeding for the mother and the infant against the potential risks of minimal budesonide exposure in the infant.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="nelsonjk1279067656532"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness in children six months to 12 months of age has been evaluated but not established.  Safety and effectiveness in children 12 months to 8 years of age have been established [see <span class="Italics"><a href="#nelsonjk1279119688736">Clinical Pharmacology, Pharmacodynamics (12.2)</a>, and <a href="#nelsonjk1279119707252">Adverse Reactions, Clinical Trials Experience (6.1)</a></span>].    </p>
<p>A 12-week study in 141 pediatric patients 6 to 12 months of age with mild to moderate <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> or recurrent/persistent <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span> was conducted.  All patients were randomized to receive either 0.5 mg or 1 mg of PULMICORT RESPULES or placebo once daily.  Adrenal-axis function was assessed with an ACTH stimulation test at the beginning and end of the study, and mean changes from baseline in this variable did not indicate adrenal suppression in patients who received PULMICORT RESPULES versus placebo.  However, on an individual basis, 7 patients in this study (6 in the PULMICORT RESPULES treatment arms and 1 in the placebo arm) experienced a shift from having a normal baseline stimulated cortisol level to having a subnormal level at Week 12 [see <span class="Italics"><a href="#nelsonjk1279119688736">Clinical Pharmacology, Pharmacodynamics (12.2)</a></span>].  <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span> was observed more frequently in patients treated with PULMICORT RESPULES than in patients treated with placebo, (N = 2, 1, and 0) in the PULMICORT RESPULES 0.5 mg, 1 mg, and placebo groups, respectively.</p>
<p>A dose dependent effect on growth was also noted in this 12-week trial.  Infants in the placebo arm experienced an average growth of 3.7 cm over 12 weeks compared with 3.5 cm and 3.1 cm in the PULMICORT RESPULES 0.5 mg and 1 mg arms respectively.  This corresponds to estimated mean (95% CI) reductions in 12-week growth velocity between placebo and PULMICORT RESPULES 0.5 mg of 0.2 cm (-0.6 to 1.0) and between placebo and PULMICORT RESPULES 1 mg of 0.6 cm (-0.2 to 1.4).  These findings support that the use of PULMICORT RESPULES in infants 6 to 12 months of age may result in systemic effects and are consistent with findings of <span class="product-label-link" type="condition" conceptid="4245750" conceptname="Growth retardation">growth suppression</span> in other studies with inhaled corticosteroids.    </p>
<p>Controlled clinical studies have shown that inhaled corticosteroids may cause a reduction in growth velocity in pediatric patients.  In these studies, the mean reduction in growth velocity was approximately one centimeter per year (range 0.3 to 1.8 cm per year) and appears to be related to dose and duration of exposure.  This effect has been observed in the absence of laboratory evidence of hypothalamic-pituitary-adrenal (HPA)-axis suppression, suggesting that growth velocity is a more sensitive indicator of systemic corticosteroid exposure in pediatric patients than some commonly used tests of HPA-axis function.  The long-term effects of this reduction in growth velocity associated with orally inhaled corticosteroids, including the impact on final adult height, are unknown.  The potential for “catch up? growth following discontinuation of treatment with orally inhaled corticosteroids has not been adequately studied.  </p>
<p>In a study of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> children 5-12 years of age, those treated with budesonide administered via a dry powder inhaler 200 mcg twice daily (n=311) had a 1.1-centimeter reduction in growth compared with those receiving placebo (n=418) at the end of one year; the difference between these two treatment groups did not increase further over three years of additional treatment. By the end of four years, children treated with the budesonide dry powder inhaler and children treated with placebo had similar growth velocities.  Conclusions drawn from this study may be confounded by the unequal use of corticosteroids in the treatment groups and inclusion of data from patients attaining puberty during the course of the study. The growth of pediatric patients receiving inhaled corticosteroids, including PULMICORT RESPULES, should be monitored routinely (e.g., via stadiometry).  The potential growth effects of prolonged treatment should be weighed against clinical benefits obtained and the risks and benefits associated with alternative therapies.  To minimize the systemic effects of inhaled corticosteroids, including PULMICORT RESPULES, each patient should be titrated to his/her lowest effective dose [see <span class="Italics"><a href="#nelsonjk1279119223667">Dosage and Administration (2)</a>and <a href="#nelsonjk1279067620485">Warnings and Precautions (5.8)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Of the 215 patients in 3 clinical trials of PULMICORT RESPULES in adult patients, 65 (30%) were 65 years of age or older, while 22 (10%) were 75 years of age or older.  No overall differences in safety were observed between these patients and younger patients, and other reported clinical or medical surveillance experience has not identified differences in responses between the elderly and younger patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">Formal pharmacokinetic studies using PULMICORT RESPULES have not been conducted in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. However, since budesonide is predominantly cleared by hepatic metabolism, impairment of liver function may lead to accumulation of budesonide in plasma.  Therefore, patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span> should be closely monitored.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">The potential for acute toxic effects following <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of PULMICORT RESPULES is low.  If inhaled corticosteroids are used at excessive doses for <span class="product-label-link" type="condition" conceptid="4088438" conceptname="Prolonged periods">prolonged periods</span>, systemic corticosteroid effects such as hypercorticism or <span class="product-label-link" type="condition" conceptid="4245750" conceptname="Growth retardation">growth suppression</span> may occur [see <span class="Italics"><a href="#nelsonjk1279119432632">Warnings and Precautions, Hypercorticism and Adrenal Suppression (5.6)</a></span>].  </p>
<p>In mice, the minimal lethal inhalation dose was 100 mg/kg (approximately 410 and 120 times, respectively, the maximum recommended daily inhalation dose in adults and children 12 months to 8 years of age on a mg/m<span class="Sup">2</span> basis). In rats there were no <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> at an inhalation dose of 68 mg/kg (approximately 550 and 160 times, respectively, the maximum recommended daily inhalation dose in adults and children 12 months to 8 years of age on a mg/m<span class="Sup">2</span> basis). In mice, the minimal oral lethal dose was 200 mg/kg (approximately 810 and 240 times, respectively, the maximum recommended daily inhalation dose in adults and children 12 months to 8 years of age on a mg/m<span class="Sup">2</span> basis). In rats, the minimal oral lethal dose was less than 100 mg/kg (approximately 810 and 240 times, respectively, the maximum recommended daily inhalation dose in adults and children 12 months to 8 years of age on a mg/m<span class="Sup">2</span> basis).</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="nelsonjk1279120277850"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Budesonide, the active component of PULMICORT RESPULES<span class="Sup">®</span>, is a corticosteroid designated chemically as (RS)-11β, 16α, 17, 21-tetrahydroxypregna-1, 4-diene-3, 20-dione cyclic 16, 17-acetal with butyraldehyde.  Budesonide is provided as a mixture of two epimers (22R and 22S).  The empirical formula of budesonide is C<span class="Sub">25</span>H<span class="Sub">34</span>O<span class="Sub">6</span> and its molecular weight is 430.5. Its structural formula is:</p>
<div class="Figure"><img alt="structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2e0fa140-85a0-42db-ba15-a068120076b4&amp;name=pulmicortrespules-firstimage.jpg"></div>
<p>Budesonide is a white to off-white, tasteless, odorless powder that is practically insoluble in water and in heptane, sparingly soluble in ethanol, and freely soluble in chloroform.  Its partition coefficient between octanol and water at pH 7.4 is 1.6 x 10<span class="Sup">3</span>.  </p>
<p>PULMICORT RESPULES is a sterile suspension for inhalation via jet nebulizer and contains the active ingredient budesonide (micronized), and the inactive ingredients disodium edetate, sodium chloride, sodium citrate, citric acid, polysorbate 80, and Water for Injection.  Three dose strengths are available in single-dose ampules (Respules™ ampules): 0.25 mg, 0.5 mg, and 1 mg per 2 mL RESPULES ampule.  For PULMICORT RESPULES, like all other nebulized treatments, the amount delivered to the lungs will depend on patient factors, the jet nebulizer utilized, and compressor performance.  Using the Pari-LC-Jet Plus Nebulizer/Pari Master compressor system, under <span class="Italics">in vitro</span> conditions, the mean delivered dose at the mouthpiece (% nominal dose) was approximately 17% at a mean flow rate of 5.5 L/min.  The mean nebulization time was 5 minutes or less.  PULMICORT RESPULES should be administered from jet nebulizers at adequate flow rates, via face masks or mouthpieces [see <span class="Italics"><a href="#nelsonjk1279119223667">Dosage and Administration (2)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Budesonide is an anti-inflammatory corticosteroid that exhibits potent glucocorticoid activity and weak mineralocorticoid activity. In standard <span class="Italics">in vitro</span> and animal models, budesonide has approximately a 200-fold higher affinity for the glucocorticoid receptor and a 1000-fold higher topical anti-inflammatory potency than cortisol (rat croton oil ear <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> assay).  As a measure of systemic activity, budesonide is 40 times more potent than cortisol when administered subcutaneously and 25 times more potent when administered orally in the rat thymus involution assay.  The clinical significance of these findings is unknown.</p>
<p>The activity of PULMICORT RESPULES is due to the parent drug, budesonide.  In glucocorticoid receptor affinity studies, the 22R form was two times as active as the 22S epimer.  <span class="Italics">In vitro </span>studies indicated that the two forms of budesonide do not interconvert.  </p>
<p>The precise mechanism of corticosteroid actions on <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> in <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> is not well known.  <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">Inflammation</span> is an important component in the pathogenesis of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>.  Corticosteroids have been shown to have a wide range of inhibitory activities against multiple cell types (e.g., mast cells, eosinophils, <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span>, macrophages, and <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>) and mediators (e.g., histamine, eicosanoids, leukotrienes, and cytokines) involved in allergic- and non-allergic-mediated <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>.  The anti-inflammatory actions of corticosteroids may contribute to their efficacy in <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>.</p>
<p>Studies in <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> patients have shown a favorable ratio between topical anti-inflammatory activities and systemic corticosteroid effects over a wide dose range of inhaled budesonide in a variety of formulations and delivery systems including an inhalation-driven, multi-dose dry powder inhaler and the inhalation suspension for nebulization.  This is explained by a combination of a relatively high local anti-inflammatory effect, extensive first pass hepatic degradation of orally absorbed drug (85-95%) and the low potency of metabolites (see below).</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="nelsonjk1279119688736"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">The therapeutic effects of conventional doses of orally inhaled budesonide are largely explained by its direct local action on the respiratory tract.  To confirm that systemic absorption is not a significant factor in the clinical efficacy of inhaled budesonide, a clinical study in adult patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> was performed comparing 400 mcg budesonide administered via a pressurized metered dose inhaler with a tube spacer to 1400 mcg of oral budesonide and placebo. The study demonstrated the efficacy of inhaled budesonide but not orally administered budesonide, even though systemic budesonide exposure was comparable for both treatments, indicating that the inhaled treatment is working locally in the lung. Thus, the therapeutic effect of conventional doses of orally inhaled budesonide are largely explained by its direct action on the respiratory tract.</p>
<p>Improvement in the control of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> symptoms following inhalation of PULMICORT RESPULES can occur within 2-8 days of beginning treatment, although maximum benefit may not be achieved for 4-6 weeks.  </p>
<p>Budesonide administered via a dry powder inhaler has been shown in various challenge models (including histamine, methacholine, sodium metabisulfite, and adenosine monophosphate) to decrease bronchial hyperresponsiveness in <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> patients.  The clinical relevance of these models is not certain.  </p>
<p>Pre-treatment with budesonide administered as 1600 mcg daily (800 mcg twice daily) via a dry powder inhaler for 2 weeks reduced the acute (early-phase reaction) and delayed (late-phase reaction) decrease in FEV<span class="Sub">1</span> following inhaled allergen challenge.</p>
<p><span class="Underline">HPA Axis Effects</span></p>
<p>The effects of PULMICORT RESPULES on the hypothalamic-pituitary-adrenal (HPA) axis were studied in three, 12-week, double-blind, placebo-controlled studies in 293 pediatric patients, 6 months to 8 years of age, with persistent <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>.  For most patients, the ability to increase cortisol production in response to stress, as assessed by the short cosyntropin (ACTH) stimulation test, remained intact with PULMICORT RESPULES treatment at recommended doses.  In the subgroup of children age 6 months to 2 years (n=21) receiving a total daily dose of PULMICORT RESPULES equivalent to 0.25 mg (n=5), 0.5 mg (n=5), 1 mg (n=8), or placebo (n=3), the mean change from baseline in ACTH-stimulated cortisol levels showed a decline in peak stimulated cortisol at 12 weeks compared to an increase in the placebo group.  These mean differences were not statistically significant compared to placebo.  Another 12-week study in 141 pediatric patients 6 to 12 months of age with mild to moderate <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> or recurrent/persistent <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span> was conducted.  All patients were randomized to receive either 0.5 mg or 1 mg of PULMICORT RESPULES or placebo once daily.  A total of 28, 17, and 31 patients in the PULMICORT RESPULES 0.5 mg, 1 mg, and placebo arms respectively, had an evaluation of serum cortisol levels post-ACTH stimulation both at baseline and at the end of the study.  The mean change from baseline to Week 12 ACTH-stimulated minus basal plasma cortisol levels did not indicate adrenal suppression in patients treated with PULMICORT RESPULES versus placebo.  However, 7 patients in this study (4 of whom received PULMICORT RESPULES 0.5 mg, 2 of whom received PULMICORT RESPULES 1 mg and 1 of whom received placebo) showed a shift from normal baseline stimulated cortisol level (≥500 nmol/L) to a subnormal level (&lt;500 nmol/L) at Week 12.  In 4 of these patients receiving PULMICORT RESPULES, the cortisol values were near the cutoff value of 500 nmol/L.</p>
<p>The effects of PULMICORT RESPULES at doses of 0.5 mg twice daily, and 1 mg and 2 mg twice daily (2 times and 4 times the highest recommended total daily dose, respectively) on 24-hour urinary cortisol excretion were studied in 18 patients between 6 to 15 years of age with persistent <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> in a cross-over study design (4 weeks of treatment per dose level).  There was a dose-related decrease in urinary cortisol excretion at 2 and 4 times the recommended daily dose.  The two higher doses of PULMICORT RESPULES (1 and 2 mg twice daily) showed statistically significantly reduced (43-52%) urinary cortisol excretion compared to the run-in period. The highest recommended dose of PULMICORT RESPULES, 1 mg total daily dose, did not show statistically significantly reduced urinary cortisol excretion compared to the run-in period. </p>
<p> PULMICORT RESPULES, like other inhaled corticosteroid products, may impact the HPA axis, especially in susceptible individuals, in younger children, and in patients given high doses for <span class="product-label-link" type="condition" conceptid="4088438" conceptname="Prolonged periods">prolonged periods</span> [see <span class="Italics"><a href="#nelsonjk1279119568739">Warnings and Precautions (5.5)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="nelsonjk1279119335993"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First"><span class="Italics">Absorption: </span></p>
<p>In <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> children 4-6 years of age, the total absolute bioavailability (ie, lung + oral) following administration of PULMICORT RESPULES via jet nebulizer was approximately 6% of the labeled dose.  </p>
<p>In children, a peak plasma concentration of 2.6 nmol/L was obtained approximately 20 minutes after nebulization of a 1 mg dose.  Systemic exposure, as measured by AUC and C<span class="Sub">max</span>, is similar for young children and adults after inhalation of the same dose of PULMICORT RESPULES.  </p>
<p><span class="Italics">Distribution:</span></p>
<p>In <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> children 4-6 years of age, the volume of distribution at steady-state of budesonide was 3 L/kg, approximately the same as in healthy adults.  Budesonide is 85-90% bound to plasma proteins, the degree of binding being constant over the concentration range (1-100 nmol/L) achieved with, and exceeding, recommended doses. Budesonide showed little or no binding to corticosteroid-binding globulin.  Budesonide rapidly equilibrated with red blood cells in a concentration independent manner with a blood/plasma ratio of about 0.8.</p>
<p><span class="Italics">Metabolism:</span></p>
<p><span class="Italics">In vitro</span> studies with human liver homogenates have shown that budesonide is rapidly and extensively metabolized.  Two major metabolites formed via cytochrome P450 (CYP) isoenzyme 3A4 (CYP3A4) catalyzed biotransformation have been isolated and identified as 16α-hydroxyprednisolone and 6β-hydroxybudesonide.  The corticosteroid activity of each of these two metabolites is less than 1% of that of the parent compound.  No qualitative difference between the <span class="Italics">in vitro</span> and <span class="Italics">in vivo</span> metabolic patterns has been detected.  Negligible metabolic inactivation was observed in human lung and serum preparations.  </p>
<p><span class="Italics">Excretion/Elimination:</span></p>
<p>Budesonide is primarily cleared by the liver.  Budesonide is excreted in urine and feces in the form of metabolites.  In adults, approximately 60% of an intravenous radiolabeled dose was recovered in the urine.  No unchanged budesonide was detected in the urine.   </p>
<p>In <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> children 4-6 years of age, the terminal half-life of budesonide after nebulization is 2.3 hours, and the systemic clearance is 0.5 L/min, which is approximately 50% greater than in healthy adults after adjustment for differences in weight.  </p>
<p><span class="Italics">Special Populations:</span> No differences in pharmacokinetics due to race, gender, or age have been identified.  </p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span>:</span></p>
<p>Reduced liver function may affect the elimination of corticosteroids.  The pharmacokinetics of budesonide were affected by compromised liver function as evidenced by a doubled systemic availability after oral ingestion.  The intravenous pharmacokinetics of budesonide were, however, similar in cirrhotic patients and in healthy adults.  </p>
<p><span class="Italics">Nursing Mothers:</span> The disposition of budesonide when delivered by inhalation from a dry powder inhaler at doses of 200 or 400 mcg twice daily for at least 3 months was studied in eight lactating women with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> from 1 to 6 months postpartum.  Systemic exposure to budesonide in these women appears to be comparable to that in non-lactating women with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> from other studies.  Breast milk obtained over eight hours post-dose revealed that the maximum concentration of budesonide for the 400 and 800 mcg doses was 0.39 and 0.78 nmol/L, respectively, and occurred within 45 minutes after dosing. The estimated oral daily dose of budesonide from breast milk to the infant is approximately 0.007 and 0.014 mcg/kg/day for the two dose regimens used in this study, which represents approximately 0.3% to 1% of the dose inhaled by the mother.  Budesonide levels in plasma samples obtained from five infants at about 90 minutes after breast-feeding (and about 140 minutes after drug administration to the mother) were below quantifiable levels (&lt;0.02 nmol/L in four infants and &lt;0.04 nmol/L in one infant) [see <span class="Italics"><a href="#nelsonjk1279119665034">Use In Specific Populations, Nursing Mothers (8.3)</a></span>].</p>
<p><span class="Italics">Drug-Drug Interactions</span></p>
<p>Inhibitors of cytochrome P450 enzymes</p>
<p>Ketoconazole: Ketoconazole, a strong inhibitor of cytochrome P450 (CYP) isoenzyme 3A4 (CYP3A4), the main metabolic enzyme for corticosteroids, increased plasma levels of orally ingested budesonide [see <span class="Italics"><a href="#nelsonjk1279119598129">Warnings and Precautions (5.12)</a>and <a href="#nelsonjk1279119306431">Drug Interactions (7.1)</a></span>].</p>
<p>Cimetidine: At recommended doses, cimetidine, a non-specific inhibitor of CYP enzymes, had a slight but clinically insignificant effect on the pharmacokinetics of oral budesonide.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">In a two-year study in Sprague-Dawley rats, budesonide caused a statistically significant increase in the incidence of <span class="product-label-link" type="condition" conceptid="4019491" conceptname="Glioma">gliomas</span> in male rats at an oral dose of 50 mcg/kg (approximately 0.4 and 0.1 times, respectively, the maximum recommended daily inhalation dose in adults and children 12 months to 8 years of age on a mcg/m<span class="Sup">2</span> basis). No tumorigenicity was seen in male rats at oral doses up to 25 mcg/kg (approximately 0.2 and 0.06 times, respectively, the maximum recommended daily inhalation dose in adults and children 12 months to 8 years of age on a mcg/m<span class="Sup">2</span> basis) and in female rats at oral doses up to 50 mcg/kg (approximately 0.4 and 0.1 times, respectively, the maximum recommended daily inhalation dose in adults and children 12 months to 8 years of age on a mcg/m<span class="Sup">2</span> basis). In two additional two-year studies in male Fischer and Sprague-Dawley rats, budesonide caused no <span class="product-label-link" type="condition" conceptid="4019491" conceptname="Glioma">gliomas</span> at an oral dose of 50 mcg/kg (approximately 0.4 and 0.1 times, respectively, the maximum recommended daily inhalation dose in adults and children 12 months to 8 years of age on a mcg/m<span class="Sup">2</span> basis). However, in the male Sprague- Dawley rats, budesonide caused a statistically significant increase in the incidence of hepatocellular tumors at an oral dose of 50 mcg/kg (approximately 0.4 and 0.1 times, respectively, the maximum recommended daily inhalation dose in adults and children 12 months to 8 years of age on a mcg/m<span class="Sup">2</span> basis). The concurrent reference corticosteroids (prednisolone and triamcinolone acetonide) in these two studies showed similar findings. </p>
<p> In a 91-week study in mice, budesonide caused no treatment-related carcinogenicity at oral doses up to 200 mcg/kg (approximately 0.8 and 0.2 times, respectively, the maximum recommended daily inhalation dose in adults and children 12 months to 8 years of age on a mcg/m<span class="Sup">2</span> basis).  </p>
<p>Budesonide was not mutagenic or clastogenic in six different test systems:  Ames <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span></span>/microsome plate test, mouse micronucleus test, mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> test, chromosome aberration test in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, sex-linked recessive lethal test in <span class="Italics">Drosophila melanogaster</span>, and DNA repair analysis in rat hepatocyte culture.  </p>
<p>In rats, budesonide had no effect on fertility at subcutaneous doses up to 80 mcg/kg approximately 0.6 times the maximum recommended daily inhalation dose in adults on a mcg/m<span class="Sup">2</span> basis. However, it caused a decrease in prenatal viability and viability in the pups at birth and during lactation, along with a decrease in maternal body-<span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, at subcutaneous doses of 20 mcg/kg and above approximately 0.2 times than the maximum recommended daily inhalation dose in adults on a mcg/m<span class="Sup">2</span> basis. No such effects were noted at 5 mcg/kg (approximately 0.04 times the maximum recommended daily inhalation dose in adults on a mcg/m<span class="Sup">2</span> basis).</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="section-12.2"></a><p></p>
<h2>13.2 Animal Toxicology Reproductive Toxicology</h2>
<p class="First">As with other corticosteroids, budesonide was teratogenic and embryocidal in rabbits and rats. Budesonide produced fetal loss, decreased pup weights, and skeletal abnormalities at a subcutaneous dose of 25 mcg/kg in rabbits (approximately 0.4 times the maximum recommended daily inhalation dose in adults on a mcg/m<span class="Sup">2</span> basis) and at a subcutaneous dose of 500 mcg/kg in rats (approximately 4 times the maximum recommended daily inhalation dose in adults on a mcg/m<span class="Sup">2</span> basis). In another study in rats, no teratogenic or embryocidal effects were seen at inhalation doses up to 250 mcg/kg (approximately 2 times the maximum recommended daily inhalation dose in adults on a mcg/m<span class="Sup">2</span> basis).</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">Three double-blind, placebo-controlled, parallel group, randomized U.S. clinical trials of 12-weeks duration each were conducted in 1018 pediatric patients, 6 months to 8 years of age, 657 males and 361 females (798 Caucasians, 140 Blacks, 56 Hispanics, 3 Asians, 21 Others) with persistent <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> of varying disease duration (2 to 107 months) and severity.  Doses of 0.25 mg, 0.5 mg, and 1 mg administered either once or twice daily were compared to placebo to provide information about appropriate dosing to cover a range of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> severity.  A Pari-LC-Jet Plus Nebulizer (with a face mask or mouthpiece) connected to a Pari Master compressor was used to deliver PULMICORT RESPULES to patients in the 3 U.S. controlled clinical trials.  The co-primary endpoints were nighttime and daytime <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> symptom scores (0-3 scale).  Improvements were addressed in terms of the primary efficacy variables of changes from baseline to the double-blind treatment period in nighttime and daytime <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> symptom scores (scale 0-3) as recorded in the patient diaries.  Baseline was defined as the mean of the last seven days prior to randomization).  The double-blind treatment period was defined as the mean over 12 week treatment period.  Each of the five doses discussed below were studied in one or two, but not all three of the U.S. studies.  </p>
<p>Results of the 3 controlled clinical trials for recommended dosages of budesonide inhalation suspension (0.25 mg to 0.5 mg once or twice daily, or 1 mg once daily, up to a total daily dose of 1 mg) in 946 patients, 12 months to 8 years of age, are presented below.  Statistically significant decreases in nighttime and daytime symptom scores of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> were observed at PULMICORT RESPULES doses of 0.25 mg once daily (one study), 0.25 mg twice daily, and 0.5 mg twice daily compared to placebo.  Use of PULMICORT RESPULES resulted in statistically significant decreases in either nighttime or daytime symptom scores, but not both, at doses of 1 mg once daily, and 0.5 mg once daily (one study).  Symptom reduction in response to PULMICORT RESPULES occurred across gender and age.  Statistically significant reductions in the need for bronchodilator therapy were also observed at all the doses of PULMICORT RESPULES studied.</p>
<p>Improvements in lung function were associated with PULMICORT RESPULES in the subgroup of patients capable of performing lung function testing.  Statistically significant increases were seen in FEV<span class="Sub">1</span> [PULMICORT RESPULES 0.5 mg once daily and 1 mg once daily (one study); 0.5 mg twice daily] and morning PEF  [PULMICORT RESPULES 1 mg once daily (one study); 0.25 mg twice daily; 0.5 mg twice daily] compared to placebo.</p>
<p>A numerical reduction in nighttime and daytime symptom scores (0-3 scale) of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> was observed within 2-8 days, although maximum benefit was not achieved for 4-6 weeks after starting treatment.  The reduction in nighttime and daytime <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> symptom scores was maintained throughout the 12 weeks of the double-blind trials.  </p>
<p><span class="Bold">Patients Not Receiving Inhaled Corticosteroid Therapy</span></p>
<p>The efficacy of PULMICORT RESPULES at doses of 0.25 mg, 0.5 mg, and 1 mg once daily was evaluated in 344 pediatric patients, 12 months to 8 years of age, with mild to moderate persistent <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> (mean baseline nighttime <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> symptom scores of the treatment groups ranged from 1.07 to 1.34) who were not well controlled by bronchodilators alone.  The changes from baseline to Weeks 0-12 in nighttime <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> symptom scores are shown in Figure 1.  Nighttime <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> symptom scores showed statistically significant decreases in the patients treated with PULMICORT RESPULES compared to placebo.  Similar decreases were also observed for daytime <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> symptom scores.</p>
<p>Changes from baseline to the double-blind phase for the budesonide treatment groups compared to placebo were made using analysis of variance techniques.  The model included terms for the respective changes from baseline as the dependent variable and terms for treatment, center and treatment by center interaction as exploratory variables. (See Figures 1-3).</p>
<p>Figure 1:	A 12-Week Trial in Pediatric Patients Not on Inhaled Corticosteroid Therapy Prior to Study Entry. Nighttime <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span> Change from Baseline</p>
<div class="Figure"><img alt="figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2e0fa140-85a0-42db-ba15-a068120076b4&amp;name=pulmicortrespules-figone.jpg"></div>
<p>p-value – 0.25 mg: 0.001, 0.5mg: 0.010, 1.0 mg: 0.009</p>
<p><span class="Bold">Patients Previously Maintained on Inhaled Corticosteroids</span></p>
<p>The efficacy of PULMICORT RESPULES at doses of 0.25 mg and 0.5 mg twice daily was evaluated in 133 pediatric <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> patients, 4 to 8 years of age, previously maintained on inhaled corticosteroids (mean FEV<span class="Sub">1</span> 79.5% predicted; mean baseline nighttime <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> symptom scores of the treatment groups ranged from 1.04 to 1.18; mean baseline dose of beclomethasone dipropionate of 265 mcg/day, ranging between 42 to 1008 mcg/day; mean baseline dose of triamcinolone acetonide of 572 mcg/day, ranging between 200 to 1200 mcg/day).  The changes from baseline to Weeks 0-12 in nighttime <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> symptom scores are shown in Figure 2.  Nighttime <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> symptom scores showed statistically significantly decrease in patients treated with PULMICORT RESPULES compared to placebo.  Similar decreases were also observed for daytime <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> symptom scores.</p>
<p>Statistically significant increases in FEV<span class="Sub">1</span> compared to placebo were observed with PULMICORT RESPULES at a dose of 0.5 mg twice daily and in morning PEF for both doses (0.25 mg and 0.5 mg twice daily).</p>
<p>Figure 2:	A 12-Week Trial in Pediatric Patients Previously Maintained on Inhaled Corticosteroid Therapy Prior to Study Entry. Nighttime <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span> Change from Baseline</p>
<div class="Figure"><img alt="figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2e0fa140-85a0-42db-ba15-a068120076b4&amp;name=pulmicortrespules-figtwo.jpg"></div>
<p>p-values: 0.25 mg: 0.022, 0.5 mg: 0.021</p>
<p><span class="Bold">Patients Receiving Once-Daily or Twice-Daily Dosing</span></p>
<p>The efficacy of PULMICORT RESPULES at doses of 0.25 mg once daily, 0.25 mg twice daily, 0.5 mg twice daily, and 1 mg once daily, was evaluated in 469 pediatric patients 12 months to 8 years of age (mean baseline nighttime <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> symptom scores of the treatment groups ranged from 1.13 to 1.31).  Approximately 70% were not previously receiving inhaled corticosteroids.  The changes from baseline to Weeks 0-12 in nighttime <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> symptom scores are shown in Figure 3.  PULMICORT RESPULES at doses of 0.25 mg and 0.5 mg twice daily, and 1 mg once daily, demonstrated statistically significant decreases in nighttime <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> symptom scores compared to placebo.  Similar decreases were also observed for daytime <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> symptom scores. </p>
<p>PULMICORT RESPULES at a dose of 0.5 mg twice daily resulted in statistically significant increases compared to placebo in FEV1, and at doses of 0.25 mg and 0.5 mg twice daily and 1 mg once daily statistically significant increases in morning PEF.  </p>
<p>The evidence supports the efficacy of the same nominal dose of PULMICORT RESPULES administered on either a once-daily or twice-daily schedule.  However, when all measures are considered together, the evidence is stronger for twice-daily dosing [see <span class="Italics"><a href="#nelsonjk1279119223667">DOSAGE AND ADMINISTRATION (2)</a></span>].  </p>
<p>Figure 3:	A 12-Week Trial in Pediatric Patients Either Maintained on Bronchodilators Alone or Inhaled Corticosteroid Therapy Prior to Study Entry. Nighttime <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span> Change from Baseline</p>
<div class="Figure"><img alt="figure three" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2e0fa140-85a0-42db-ba15-a068120076b4&amp;name=pulmicortrespules-figthree.jpg"></div>
<p>p-values:  0.25 mg qd: 0.121, 0.25 mg bid: &lt;0.001, 0.5 mg bid: 0.003, 1.0 mg qd: 0.005</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING </h1>
<p class="First">PULMICORT RESPULES is supplied in sealed aluminum foil envelopes containing one plastic strip of five single-dose RESPULES ampules together with patient instructions for use.  There are 30 RESPULES ampules in a carton.  Each single-dose RESPULES ampule contains 2 mL of sterile liquid suspension.  </p>
<p>PULMICORT RESPULES is available in three strengths, each containing 2 mL:</p>
<p>NDC 54868-5774-0              0.25 mg/2 mL</p>
<p>NDC 54868-5621-0              0.5 mg/2 mL<br></p>
<p><br></p>
<p>PULMICORT RESPULES should be stored upright at controlled room temperature 20-25°C (68-77°F) [see USP], and protected from light.  When an envelope has been opened, the shelf life of the unused RESPULES ampules is 2 weeks when protected.  After opening the aluminum foil envelope, the unused RESPULES ampules should be returned to the aluminum foil envelope to protect them from light.  Any opened RESPULES ampule must be used promptly.  Gently shake the RESPULES ampule using a circular motion before use.  Keep out of reach of children.  Do not freeze.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<div class="Section" data-sectionCode="34076-0">
<a name="section-15.1"></a><p></p>
<h2></h2>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="nelsonjk1279120227289"></a><a name="section-15.2"></a><p></p>
<h2>17.1 Administration with a Jet Nebulizer</h2>
<p class="First">Patients should be advised that PULMICORT RESPULES should be administered with a jet nebulizer connected to a compressor with an adequate air flow, equipped with a mouthpiece or suitable face mask. Ultrasonic nebulizers are not suitable for the adequate administration of PULMICORT RESPULES and, therefore, are not recommended. The effects of mixing PULMICORT RESPULES with other nebulizable medications have not been adequately assessed.  PULMICORT RESPULES should be administered separately in the nebulizer [see <span class="Italics"><a href="#nelsonjk1279119223667">Dosage and Administration (2)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.3"></a><p></p>
<h2>17.2 <span class="product-label-link" type="condition" conceptid="29735" conceptname="Candidiasis of mouth">Oral Candidiasis</span></h2>
<p class="First">Patients should be advised that <span class="product-label-link" type="condition" conceptid="4018050" conceptname="Localized infection">localized infections</span> with <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> albicans</span> occurred in the mouth and pharynx in some patients. If <span class="product-label-link" type="condition" conceptid="4080451" conceptname="Pharyngeal candidiasis">oropharyngeal candidiasis</span> develops, it should be treated with appropriate local or systemic (i.e. oral) antifungal therapy while still continuing therapy with PULMICORT RESPULES, but at times therapy with PULMICORT RESPULES may need to be temporarily interrupted under close medical supervision. Rinsing the mouth after inhalation is advised [see <span class="Italics"><a href="#nelsonjk1279119355555">Warnings and Precautions (5.1)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.4"></a><p></p>
<h2>17.3 Not for Acute Symptoms</h2>
<p class="First">PULMICORT RESPULES is not meant to relieve acute <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> symptoms and extra doses should not be used for that purpose. Acute symptoms should be treated with an inhaled, short-acting beta<span class="Sub">2</span>-agonist such as albuterol. (The healthcare professional should provide that patient with such medication and instruct the patient in how it should be used.)  Patients should be instructed to notify their healthcare professional immediately if they experience any of the following:</p>
<ul>
<li><p class="First">Decreasing effectiveness of inhaled, short-acting beta<span class="Sub">2</span>- agonists </p></li>
<li><p class="First">Need for more inhalations than usual of inhaled, short-acting beta<span class="Sub">2</span>-agonists</p></li>
<li><p class="First">Significant decrease in lung function as outlined by the physician</p></li>
</ul>
<p>Patients should not stop therapy with PULMICORT RESPULES without physician/provider guidance since symptoms may recur after discontinuation [see <span class="Italics"><a href="#nelsonjk1279120044261">Warnings and Precautions (5.2)</a></span>]</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.5"></a><p></p>
<h2>17.4 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">contact dermatitis</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, and <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> have been reported with use of PULMICORT RESPULES.  Discontinue PULMICORT RESPULES if such reactions occur [see <span class="Italics"><a href="#nelsonjk1279067428237">Contraindications (4) and</a><a href="#nelsonjk1279119388961">Warning and Precautions (5.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.6"></a><p></p>
<h2>17.5 <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">Immunosuppression</span></h2>
<p class="First">Patients who are on immunosuppressant doses of corticosteroids should be warned to avoid exposure to <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span> or <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span> and, if exposed, to consult their physician without delay. If exposure to such a person occurs, and the child has not had chicken pox or been properly vaccinated, a physician should be consulted without delay. Patients should be informed of potential worsening of existing <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>, fungal, bacterial, viral, or parasitic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, or ocular herpes simplex [see <span class="Italics"><a href="#nelsonjk1279119412992">Warnings and Precautions (5.4)</a></span>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.7"></a><p></p>
<h2>17.6 Hypercorticism and Adrenal Suppression</h2>
<p class="First">Patients should be advised that PULMICORT RESPULES may cause systemic corticosteroid effects of hypercorticism and adrenal suppression. Additionally, patients should be instructed that <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> due to <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span> have occurred during and after transfer from systemic corticosteroids. Patients should taper slowly from systemic corticosteroids if transferring to PULMICORT RESPULES [see <span class="Italics"><a href="#nelsonjk1279119432632">Warnings and Precautions (5.6)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.8"></a><p></p>
<h2>17.7 Reduction in Bone Mineral Density</h2>
<p class="First">Patients who are at an increased risk for decreased BMD should be advised that the use of corticosteroids may pose an additional risk [see <span class="Italics"><a href="#nelsonjk1279119451835">Warnings and Precautions (5.7)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.9"></a><p></p>
<h2>17.8 Reduced Growth Velocity</h2>
<p class="First">Patients should be informed that orally inhaled corticosteroids, including PULMICORT RESPULES, may cause a reduction in growth velocity when administered to pediatric patients.  Healthcare professionals should closely follow the growth of children and adolescents taking corticosteroids by any route [see <span class="Italics"><a href="#nelsonjk1279067620485">Warnings and Precautions (5.8)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.10"></a><p></p>
<h2>17.9 Ocular Effects</h2>
<p class="First">Long-term use of inhaled corticosteroids may increase the risk of some eye problems (<span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataracts</span> or <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>); regular eye examinations should be considered [see <span class="Italics"><a href="#nelsonjk1279066943771">Warnings and Precautions (5.9)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.11"></a><p></p>
<h2>17.10  Use Daily</h2>
<p class="First">Patients should be advised to use PULMICORT RESPULES at regular intervals once or twice a day, since its effectiveness depends on regular use. Maximum benefit may not be achieved for 4 to 6 weeks or longer after starting treatment. If symptoms do not improve in that time frame or if the condition worsens, patients should be instructed to contact their healthcare professional.</p>
</div>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="section-16"></a><p></p>
<h1>17.11 FDA-Approved Patient Labeling</h1>
<p class="First"><span class="Italics">See accompanying Patient Information and Instructions for Use.</span></p>
<p><span class="Bold">Patient Information and Instructions for Use</span></p>
<p><span class="Bold">PULMICORT RESPULES (bew DEH so nide)</span></p>
<p><span class="Italics"> (budesonide) inhalation suspension</span></p>
<p>2 mL ampules containing 0.25 mg, 0.5 mg, or 1 mg </p>
<p></p>
<a name="idb01cf0f-e086-4925-8bd2-3ad75d892f9a"></a><table frame="hsides">
<colgroup><col align="left" valign="top"></colgroup>
<tbody class="Headless"><tr class="First Last"><td align="left">
<p class="First"><span class="Bold">For inhalation only.</span></p>
<p><span class="Bold">Do not swallow.</span></p>
<p><span class="Bold">Only use PULMICORT RESPULES with a jet nebulizer machine that is connected to an air compressor. Do not use with an ultrasonic nebulizer.</span></p>
</td></tr></tbody>
</table>
<p>Read the Patient Information that comes with PULMICORT RESPULES before your child starts using it and each time you get a refill.  There may be new information.  This information does not take the place of talking with your healthcare provider about your child’s medical condition or treatment.  If you have any questions about PULMICORT RESPULES, ask your healthcare provider or  pharmacist. </p>
<p><span class="Bold">What is PULMICORT RESPULES?</span></p>
<p>PULMICORT RESPULES is an inhaled corticosteroid medicine.  PULMICORT RESPULES is a long-term maintenance medicine used to control and prevent <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> symptoms in children ages 12 months to 8 years.</p>
<p>Inhaled corticosteroids help to decrease <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> in the lungs.  <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">Inflammation</span> in the lungs can lead to <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> symptoms.  PULMICORT RESPULES helps reduce <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> and <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> in the lungs, and helps keep the airways open to reduce <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> symptoms.</p>
<p><span class="Bold">PULMICORT RESPULES does not treat the sudden symptoms (<span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, and <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> or tightness) of an <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attack.  Always have a short-acting beta2-agonist medicine (rescue inhaler) with you to treat sudden symptoms.  If your child does not have an inhaled, short-acting bronchodilator, ask your  healthcare provider to have one prescribed for your child.</span></p>
<p>It is not known if PULMICORT RESPULES is safe or effective in children younger than 12 months or older than 8 years.</p>
<p><span class="Bold">Who should not use PULMICORT RESPULES?</span></p>
<p><span class="Bold">Do not use PULMICORT RESPULES:</span></p>
<p><span class="Bold">·	to treat sudden symptoms of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span></span></p>
<p><span class="Bold">·	if your child is allergic to budesonide or any of the ingredients in PULMICORT RESPULES.  See the end of this leaflet for a complete list of ingredients in PULMICORT RESPULES.</span></p>
<p><span class="Bold">What should I tell my healthcare provider before using PULMICORT RESPULES? </span></p>
<p>Before your child uses PULMICORT RESPULES, tell your healthcare provider if your child:</p>
<p><span class="Bold">·</span>	has an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span>.  See the section “Who should not use PULMICORT RESPULES?  There is a complete list of ingredients in PULMICORT RESPULES at the end of this leaflet.</p>
<p><span class="Bold">·</span>	has or recently had chicken pox or <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>, or has recently been near anyone with chicken pox or <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>.</p>
<p><span class="Bold">·</span>	has or had <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> of the respiratory tract.</p>
<p><span class="Bold">·	</span>has certain kinds of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that have not been treated, including:</p>
<p> o	<span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span></p>
<p> o	<span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span></p>
<p> o	<span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span></p>
<p> o	parasitic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span></p>
<p> o	herpes simplex <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> of the eye (ocular herpes simplex)</p>
<p>PULMICORT RESPULES may not be right for children who have had any of these types of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</p>
<p><span class="Bold">·</span>	has decreased bone mineral density (bone strength).  Your child is at risk for decreased bone mineral density if he or she:</p>
<p> o	is inactive for a long period of time</p>
<p> o	has a family history of <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span></p>
<p> o	does not eat well (poor nutrition)</p>
<p> o	takes bone thinning medicines (such as anticonvulsant medicines or corticosteroids) for a long time.</p>
<p><span class="Bold">·</span>	has an eye problem such as increased pressure in the eye, <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> or <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataracts</span>.</p>
<p><span class="Bold">·</span>	has liver problems</p>
<p><span class="Bold">·</span>	is planning to have surgery.</p>
<p><span class="Bold">·</span>	has any other medical conditions.</p>
<p><span class="Bold">·</span>	is pregnant or plans to become pregnant. It is not known if PULMICORT RESPULES will harm your unborn baby. </p>
<p><span class="Bold">·</span>	is breast-feeding or plans to breast-feed. PULMICORT RESPULES can pass into breast milk. You and your  healthcare provider should decide if you will use PULMICORT RESPULES or breast-feed.</p>
<p>Tell your healthcare provider about all the medicine your child takes, including prescription and non-prescription medicines, vitamins, and herbal supplements. </p>
<p>Using PULMICORT RESPULES with certain other medicines may affect each other causing side effects. Especially tell your healthcare provider if your child takes:</p>
<p><span class="Bold">·</span> 	corticosteroids</p>
<p><span class="Bold">·</span>	anti-<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> medicine (anticonvulsants)</p>
<p><span class="Bold">·</span> 	medicines that suppress the immune system (immunosuppressant)</p>
<p><span class="Bold">·</span> 	ketoconazale (Nizoral)</p>
<p><span class="Bold">· </span>	certain medicines that can affect how your liver breaks down medicine</p>
<p>Ask your healthcare provider or pharmacist for a list of these medicines, if you are not sure.</p>
<p>Know the medicines your child takes. Keep a list of them and show it to your healthcare provider and pharmacist when your child gets a new medicine.</p>
<p><span class="Bold">How should I use PULMICORT RESPULES?</span></p>
<p><span class="Bold">·</span>	Use PULMICORT RESPULES exactly as prescribed by your healthcare provider.  Your child must use PULMICORT RESPULES regularly for it to work.</p>
<p><span class="Bold">·</span>	PULMICORT RESPULES comes in three strengths.  Your healthcare provider has prescribed the strength that is best for your child.</p>
<p><span class="Bold">·</span>	Do not stop using PULMICORT RESPULES, and do not change your child’s dose of PULMICORT RESPULES without talking to your healthcare provider. </p>
<p><span class="Bold">·</span> PULMICORT RESPULES is for inhaled use only.  Use PULMICORT RESPULES with a jet nebulizer connected to an air compressor set up with a mouthpiece or face mask.  Do not use an ultrasonic nebulizer to give PULMICORT RESPULES.</p>
<p><span class="Bold">·</span>	Do not mix PULMICORT RESPULES with other nebulizer medicines.  If you child uses another medicine by inhalation to treat <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, talk with your healthcare provider for instructions on when to use the other medicine. </p>
<p><span class="Bold">·</span>	If your child misses a dose, just give the next regularly scheduled dose when it is due.  Do not use PULMICORT RESPULES more often than has been prescribed.</p>
<p><span class="Bold">·</span>	Improvement in the control of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> symptoms with PULMICORT RESPULES can occur within 2-8 days.  It may take up to 4-6 weeks before maximum improvement is seen. </p>
<p><span class="Bold">·</span>	Make sure your child always has a short-acting beta<span class="Sub">2</span>-agonist medicine with him or her.  Your child should use the short-acting beta<span class="Sub">2</span>-agonist medicine for breathing problems between doses of PULMICORT RESPULES or if a sudden <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attack happens.  Call your healthcare provider right away if: </p>
<p> o	the short-acting rescue medicine does not work as well for relieving <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> symptoms. </p>
<p> o	your child needs to use the short-acting rescue medicines more often than usual. </p>
<p> o	your child’s breathing problems worsen with PULMICORT RESPULES </p>
<p><span class="Bold">·</span>	Rinse your child’s mouth with water and have him or her spit the water out after each PULMICORT RESPULES treatment.  Do not swallow the water.  This will lessen the chance of getting a <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infection</span> (<span class="product-label-link" type="condition" conceptid="29735" conceptname="Candidiasis of mouth">thrush</span>) in the mouth.</p>
<p><span class="Bold">·</span>	If your child has used long-term corticosteroids and the dose is now being lowered or stopped, a warning card should be carried stating that your child may need corticosteroids during times of stress or during an <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attack that does not get better with bronchodilator medicines. </p>
<p><span class="Bold">·</span>	Your healthcare provider may check your child’s blood, breathing and do eye exams while using PULMICORT RESPULES. </p>
<p><span class="Bold">·	</span>Read the Patient Information and Instructions for Use at the end of this leaflet for detailed instructions about how to use PULMICORT RESPULES.</p>
<p><span class="Bold">What are the possible side effects of PULMICORT RESPULES?</span></p>
<p>PULMICORT RESPULES may cause serious side effects including:</p>
<p><span class="Bold">·</span>	<span class="product-label-link" type="condition" conceptid="29735" conceptname="Candidiasis of mouth">Thrush</span> (<span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">candida</span></span>), a <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infection</span> in your mouth and throat. Tell your healthcare provider if your child has any <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> or white colored patches in the mouth or throat.</p>
<p><span class="Bold">·</span>	Worsening of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> or sudden <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attacks.</p>
<p><span class="Bold">·</span>	<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span>.  Tell your  healthcare provider or get medical help right away if your child has:</p>
<p> o	<span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span></p>
<p> o	severe <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> </p>
<p> o	<span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face, mouth and tongue </p>
<p> o	trouble breathing or swallowing o	<span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> </p>
<p> o	<span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> (feeling of doom)</p>
<p><span class="Bold">·</span>	Immune system effects and a higher chance of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. Your child is more likely to get <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> when taking medicines that weaken the immune system.  Symptoms of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> may include:  <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">aches</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, feeling tired, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.  Tell your healthcare provider about any signs of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> while your child uses PULMICORT RESPULES.</p>
<p><span class="Bold">·</span>	<span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">Adrenal insufficiency</span>. <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">Adrenal insufficiency</span> is a condition in which the adrenal glands do not make enough steroid hormones. Symptoms of <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span> include <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">low blood pressure</span>.</p>
<p><span class="Bold">·</span>	Decrease in bone mineral density (bone strength).  Your  healthcare provider may want to check your child for this during treatment with PULMICORT RESPULES. </p>
<p><span class="Bold">·</span>	Slowed or delayed growth problems.  Your child’s healthcare provider may want to monitor your child’s growth while using PULMICORT RESPULES. </p>
<p><span class="Bold">·</span>	Eye problems, including <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> and <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataracts</span>.  Your child’s healthcare provider may suggest  eye exams while using PULMICORT RESPULES. </p>
<p><span class="Bold">·	Increased <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span> right after taking PULMICORT RESPULES.  Always have a fast-acting inhaled  bronchodilator medicine with you to treat sudden <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>. </span></p>
<p>Call your healthcare provider or get medical help right away if your child has any of the serious side effects listed above.</p>
<p>The most common side effects of PULMICORT RESPULES include:</p>
<p>·	<span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">respiratory infections</span>.  Symptoms may include stuffy nose, sore nose and throat.</p>
<p>·	<span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">runny nose</span></p>
<p>·	<span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> </p>
<p>·	<span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span></p>
<p>·	viral irritation and <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> of the stomach and intestine (<span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>).  <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">Gastroenteritis</span> symptoms may include:  stomach area <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and loss of appetite.</p>
<p>·	<span class="product-label-link" type="condition" conceptid="4044878" conceptname="Infection of ear">ear infections</span></p>
<p>·	<span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">nosebleed</span> </p>
<p>	pink eye (<span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>)</p>
<p>·	<span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> </p>
<p>Tell your healthcare provider if your child has any side effect that bothers him or her or that does not go away.  For more information, ask your healthcare provider or pharmacist.</p>
<p>Call your healthcare provider for medical advice about side effects. You may report side effects to AstraZeneca at 1-800-236-9933 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. </p>
<p><span class="Bold">How should I store PULMICORT RESPULES?</span></p>
<p>·	Store PULMICORT RESPULES in an upright position between 68°F to 77°F (20°C to 25°C).</p>
<p>·	Keep PULMICORT RESPULES in the aluminium foil envelope to protect from light until ready to use.</p>
<p>·	After a PULMICORT RESPULES ampule is opened it should be used right away.</p>
<p>·	PULMICORT RESPULES ampules can be stored for 2 weeks after opening the protective aluminium foil envelope.</p>
<p>·	Throw away PULMICORT RESPULES ampules if not used within 2 weeks of opening the protective aluminium foil envelope.</p>
<p>·	Do not refrigerate or freeze.</p>
<p><span class="Bold">Keep PULMICORT RESPULES and all medicines out of the reach of children. </span></p>
<p><span class="Bold">General Information about PULMICORT RESPULES</span></p>
<p>Medicines are sometimes prescribed for conditions other than those listed in a Patient Information leaflet.  Do not use PULMICORT RESPULES for a condition for which it was not prescribed.  Do not give PULMICORT RESPULES to other people, even if they have the same symptoms that you have.  It may harm them. </p>
<p>This Patient Information leaflet summarizes the most important information about PULMICORT RESPULES.  If you would like more information, talk with your healthcare provider.  You can ask your pharmacist or healthcare provider for information about PULMICORT RESPULES that is written for health professionals.  For more information, go to www.pulmicortrespules.com or call AstraZeneca at 1-800-236-9933.</p>
<p><span class="Bold">What are the ingredients in PULMICORT RESPULES?</span></p>
<p>Active ingredient:  budesonide </p>
<p>Inactive ingredients:  disodium edetate, sodium chloride, sodium citrate, citric acid, polysorbate 80 and water for injection.</p>
<p><span class="Bold">Patient Instructions for Use</span></p>
<p><span class="Bold">Important:</span></p>
<p><span class="Bold">PULMICORT RESPULES is only for use with a jet nebulizer machine.  Make sure you know how to use your jet nebulizer machine before your child uses PULMICORT RESPULES.</span></p>
<p><span class="Bold">PULMICORT RESPULES is a liquid that is turned into a mist by a nebulizer and inhaled into the lungs.</span></p>
<p><span class="Bold">The face mask should be properly adjusted to optimize delivery and to avoid exposing the eyes to the nebulized medication.  Corticosteroid effects on the skin can be avoided if the face is washed after the use of a face mask.</span></p>
<p>1.	PULMICORT RESPULES come in a sealed protective aluminium foil envelope.</p>
<p>·	Do not open the sealed pouch until you are ready to use a dose of PULMICORT RESPULES.</p>
<p>·	Open the sealed foil envelope along the dotted line and take out 1 single-dose ampule from the strip.  See Figure 1. </p>
<p>·	Record the date that you opened the foil on the back of the envelope in the space provided. </p>
<p>Return the unopened PULMICORT RESPULES<span class="Sup">®</span> ampules on the strip back into the foil envelope before storing. </p>
<p>Figure 1</p>
<div class="Figure"><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2e0fa140-85a0-42db-ba15-a068120076b4&amp;name=pulmicortrespules-figureone.jpg"></div>
<p>2.	Gently shake the PULMICORT RESPULES ampule using a circular motion as shown in Figure 2.</p>
<p>Figure 2</p>
<div class="Figure"><img alt="Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2e0fa140-85a0-42db-ba15-a068120076b4&amp;name=pulmicortrespules-figuretwo.jpg"></div>
<p>3.	Hold the PULMICORT RESPULES ampule upright without squeezing the ampule and open by twisting off the top as shown in Figure 3.</p>
<p>Figure 3</p>
<div class="Figure"><img alt="Figure 3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2e0fa140-85a0-42db-ba15-a068120076b4&amp;name=pulmicortrespules-figurethree.jpg"></div>
<p>4.	Place the open end of the PULMICORT RESPULES ampule into the nebulizer cup (reservoir) and slowly squeeze all of the medicine from the ampule into the nebulizer medicine cup as shown in Figure 4.  Throw away the empty ampule.</p>
<p>Figure 4</p>
<div class="Figure"><img alt="Figure 4" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2e0fa140-85a0-42db-ba15-a068120076b4&amp;name=pulmicortrespules-figurefour.jpg"></div>
<p></p>
<p>5.	Use your jet nebulizer as directed.</p>
<p></p>
<p>All trademarks are the property of the AstraZeneca group of companies. </p>
<p><span class="Sup">©</span>AstraZeneca 2007, 2010  </p>
<p>Manufactured for:  AstraZeneca LP, Wilmington, DE  19850 </p>
<p>By:  AstraZeneca AB, Sodertalje, Sweden </p>
<p>Product of Sweden  </p>
<p>Rev.   07/2010</p>
<p></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.1"></a><p></p>
<p class="First"><span class="Bold">Additional barcode labeling by:</span><br>Physicians Total Care, Inc.<br>Tulsa, Oklahoma       74146</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<h1>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</h1>
<span class="Bold">PULMICORT RESPULES</span><br><br>0.25 mg/2 mL<br>30 RESPULES ampules<br><div class="Figure"><img alt="Pulmicort Respules 0.25mg/2mL - 30 single dose respules ampule carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2e0fa140-85a0-42db-ba15-a068120076b4&amp;name=5774.jpg"></div>
<br><br><br>0.5 mg/2 mL<br>30 RESPULES ampules<br><br><div class="Figure"><img alt="Pulmicort Respules 0.5mg/2mL - 30 single dose respules ampule carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2e0fa140-85a0-42db-ba15-a068120076b4&amp;name=5621.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PULMICORT RESPULES 		
					</strong><br><span class="contentTableReg">budesonide suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-5774(NDC:0186-1988)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">RESPIRATORY (INHALATION)</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>BUDESONIDE</strong> (BUDESONIDE) </td>
<td class="formItem">BUDESONIDE</td>
<td class="formItem">0.25 mg  in 2 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>EDETATE DISODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CITRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ANHYDROUS CITRIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-5774-0</td>
<td class="formItem">6  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">5  in 1 POUCH</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">2 mL in 1 AMPULE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020929</td>
<td class="formItem">06/01/2007</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PULMICORT RESPULES 		
					</strong><br><span class="contentTableReg">budesonide suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-5621(NDC:0186-1989)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">RESPIRATORY (INHALATION)</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>BUDESONIDE</strong> (BUDESONIDE) </td>
<td class="formItem">BUDESONIDE</td>
<td class="formItem">0.5 mg  in 2 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>EDETATE DISODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CITRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ANHYDROUS CITRIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-5621-0</td>
<td class="formItem">6  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">5  in 1 POUCH</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">2 mL in 1 AMPULE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020929</td>
<td class="formItem">06/29/2006</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 6/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>96fd8eb0-93c6-4d08-ae0d-7b8fe4c44354</div>
<div>Set id: 2e0fa140-85a0-42db-ba15-a068120076b4</div>
<div>Version: 2</div>
<div>Effective Time: 20120604</div>
</div>
</div> <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
